A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Exclusion Criteria

• •Previous treatment with a poly ADP-ribose polymerase (PARP) inhibitor.
• •Patients who have had radiotherapy within 2 weeks or participated in another clinical trial with any investigational agents within 2 weeks prior to study screening.
• •Previous treatment using CYP3A4 inducers within 3 weeks or inhibitors within 2 weeks.
• •Significant cardiovascular disease such as New York Heart Associate Class III/IV, cardiac failure, myocardial infarction, unstable arrhythmia, or evidence of ischemia on ECG within 6 months prior to enrolment.
• •Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
• •Patients with myelodysplastic syndrome/acute myeloid leukaemia.
• •Known active hepatitis B or C infection.
• •History of immunodeficiency (including HIV infection) or organ transplantation.
• •Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.